BONE RESORPTION MARKER BETA-CROSSLAPS FOR EARLY MONITORING OF OSTEOPOROSIS TREATMENT WITH DENOSUMAB

Abstract

Antiresorptive long-term treatment for osteoporosis increases bone mineral density. Due to the long duration, poor compliance of patients to medication therapy is a big challenge. Bone mineral density measurements are recommended for the monitoring of treatment, but detectable changes may take up to 2-3 years. Bone turnover markers can indicate changes in bone turnover rates earlier, and assessment their levels may be effective in enhancing compliance and clinical efficacy. Purpose: Our study aimed to assess whether the dynamics in serum levels of bone resorption marker beta-CrossLaps have a real practical benefit for early monitoring of postmenopausal osteoporosis treatment. Materials and methods: 21 Bulgarian women in menopause with newly diagnosed osteoporosis were studied. All participants hadn’t been under treatment. Serum beta-CrossLaps levels were measured before and six months after subcutaneous administration of Denosumab – Injection 60 mg. Results: Serum concentrations before and six months after starting treatment were respectively 0.589 ± 0.266 ng/ml (0.06 – 1.2) and 0.166 ± 0.139 ng/ml (0.05 – 0.59). The beta-CrossLaps pre-treatment serum levels were within the reference range for the commercial kit used. After six months of treatment, there was a significant decrease in serum concentrations of about 72% from baseline. In our study, although pre-treatment levels were within the reference range, a significant decrease in concentrations was observed. Conclusions: The results show that the dynamics of beta-CrossLaps may be useful in the early monitoring of osteoporosis treatment.

Keywords

• postmenopausal osteoporosis
• early monitoring treatment
• beta-crosslaps
• bone resorption markers
• denosumab